

Documentation - Infectious Disease Risk Screening

Digital Health Quick Reference Guide

This Quick Reference Guide will explain how to:

Document infectious disease risk screening.

Option 1- Inpatient Areas

 Infectious Disease Risk Screen is part of the Initial Patient Assessment (accessed via the Activity page on Care Compass) that is commenced on admission to an inpatient ward.

Patient	WH Test, Navigator Band	Age: 28yrs				
WH Test, Rapid Response 29ys F - No Relationship Exists	Activities PRN/Continuous Plans of Care	Patient Information				
WHS Test, Review 31yrs F - No Relationship Exists	🖉 🖻 🗑 🖉 🛛 2 Hours 🔤 4	Hours 12 Hours				
WH Test, Comp Care Completed 1	Current					
25yrs F - No Relationship Exists	🚯 Adult Risk Assessment 20/01/2020 09:06:53, Stop Date 20/01/2020 09:06:53					
WH Test, Comp Care Completed 2	Comment: Order entered secondary to in	patient admission				
22yrs F - No Relationship Exists	Basic Admission Assessment Adult 2001	2020 09:06:53, Stop Date 20/01/2	2020 09:06:53			
WH Test, Comp Care Completed 3	Comment: Order entered secondary to in	patient admission				
26yrs F No Relationship Exists	Initial Patient Assessment Adult Initial Pati	ent Assessment 20101/2020 09 0	6:53, Stop Date 2001/2020-09:06:5			
WH Test, Navigator Band	Comment: Order entered secondary to in	patient admission				
28yrs F - No Allergies Recorded	Valuables/Belongings 20/01/2020 09:06:53	Sind Date 20/01/2020 09:06:53				
Green, Avery MS	Comment: Order entered secondary to in					

2. Answer all questions to complete the **Infectious Disease Risk Screening Chapter**. There is a link to the **Standard and Transmission Based Precautions Policy** at the bottom of the page.


on: 06/02/2020 🗧 🗨 1339 🎅 AEDT						By:	Goh, M
Infectious Disease Risk	Screening						
Overseas travel in past 4 weeks							
Location of Recent Travel	O Africa O Europe O Central America O India O China O Indonesia	O Mex O Mide O Paci		O Vi			
Overnight stay in an Australian or ov	erseas hospital or aged car	e facility i	n last 12 months	O Yes	C No		
Been a patient in an Australian facilit Organisms e.g. CPE) transmission ris Right click on this box and select "Re	sk area in the last 12 month		roducing	O Yes	C No		
Any symptoms requiring transmission e.g. fever & rash, influenza-like or di				O Yes	C No		
Any symptoms requiring airborne pro shingles or TB?	ecautions? eg. measles, chi	cken pox/	'disseminated	O Yes	O No		
Contact with someone who has Carb Candida auris	apenemase-producing orga	nisims (e	.g. CPE) or	O Yes	O No		
			DO OD terrus te	O Yes	0.11		
Contact with a person with suspecte a country with widespread Novel Cor fever (now or bistory of) and/or cour	onavirus or MERS in past 4			U tes	O No		
	onavirus or MERS in past 4	weeks ANI) have either	U Tes	U No		
a country with widespread Novel Cor	onavirus or MERS in past 4 gh/ difficulty breathing Novel Coronavirus high risk	weeks ANI) have either	U Tes	U No		
a country with widespread Novel Cor fever (now or history of) and/or cou	onavirus or MERS in past 4 gh/ difficulty breathing Novel Coronavirus high risk Surveillance	weeks ANI) have either		U No		I
a country with widespread Novel Cor fever (now or history of) and/or cour Additional Syndromic/MDRO S	onavirus or MERS in past 4 gh/ difficulty breathing Novel Coronavirus high risk Surveillance	weeks ANE	D have either nina, Hong Kong]	U No		I
a country with widespread Novel Cor fever (now or history of) and/or cour Additional Syndromic/MDRO S History of CPO (includes CPE/CRE)	ronavirus or MERS in past 4 gh/ difficulty breathing Novel Coronavirus high risk Runveillance	veeks ANI	D have either nine, Hong Kong C No	 	U No		I
a country with widespread Novel Cor fever (now or history of) and/or coun Additional Syndromic/MDRO S History of CPO (includes CPE/CRE) History of clostridium difficile	ionavirus or MERS in past 4- gh/ difficulty breathing Novel Coronavirus high risk Surveillance	Countries: Ch Countries: Ch Co	D have either nine, Hong Kong O No O No	 	U No		I
a country with widespread Novel Cor fever (now or history of) and/or count Additional Syndromic/MDRO S History of CPO (includes CPE/CRE) History of CPO tostridium difficile Recent exposure to communicable d	ionavirus or MERS in past 4- gh/ difficulty breathing Novel Coronavirus high risk Surveillance	veeks ANI countries: Cl O Yes O Yes O Yes	D have either inne, Hong Kong No No No No	 	UNO		I
a country with widespread Novel Cor fever (now or history of) and/or count Additional Syndromic/MDRO S History of CPO (includes CPE/CRE) History of Clostridium difficile Recent exposure to communicable d History of Candida Auris	ionavirus or MERS in past 4- gh/ difficulty breathing Novel Coronavirus high risk Surveillance	veeks ANI countries: Cf O Yes O Yes O Yes O Yes	D have either nine. Hong Kong No No No No	 	UNO		I
a country with widespread Novel Cor fever (now or history of) and/or count Additional Syndromic/MDRO S History of CPO (includes CPE/CRE) History of COStridium difficile Recent exposure to communicable d History of Candida Auris History of abscess	ionavirus or MERS in past 4- gh/ difficulty breathing Novel Coronavirus high risk urveillance isease	veeks ANI countries: Cf O Yes O Yes O Yes O Yes O Yes	D have either inine. Hong Kong No No No No No No No No	 			L
a country with widespread Novel Cor fever (now or history of) and/or cous Additional Syndromic/MDRO S History of CPO (includes CPE/CRE) History of CPO (includes CPE/CRE) History of clostridium difficile Recent exposure to communicable d History of Candida Auris History of abscess History of chronic skin condition	- Lactamase (ESBL)	C Yes	D have either Inne. Hong Kong No	 			I
a country with widespread Novel Cor fever (now or history of) and/or coun- Additional Syndromic/MDRO S History of CPO (includes CPE/CRE) History of clostridium difficile Recent exposure to communicable d History of Candida Auris History of Candida Auris History of abscess History of chronic skin condition History of Extended- Spectrum Beta	innavirus or MERS in past 4- gh/ difficulty breathing Novel Cornevirus high risk Rurveillance isease - Lactamase (ESBL) ylococcus Aureus (MRSA)	Veeks ANI Countries: CH Ves Yes	D have either D have either No No		U No		I

P Infectious Disease Assessment - HTSTEST, Joan



Option 2 – ED, DPU & Admissions

1. Infectious Disease Risk Screen is also located in the in AdHoc > Basic Care folder.



 Answer all questions to complete the Infectious Disease Risk Screening Chapter. There is a link to the Standard and Transmission Based Precautions Policy at the bottom of the page.

	/02/2020 🚔 💌 1139 🚔 AEDT						By:	Goh, N
nission Informa	Infectious Disease Risk Scre	oning						
ctious Diseas								
rgies	Overseas travel in past 4 weeks	U NO						
blem History	Location of Recent Travel		O Me			nited States		1
cedural Histor	O Cer O Chi	na O India		tdle East O Russia cific Islands O South A	merica O D			
nily History	0.01	in C monesta	0.10			n 164.		
cial History	Overnight stay in an Australian or overseas l	hospital or aged car	e facility i	in last 12 months	O Yes	O No		1
rent Living Site					0	0.0		
morbid Informa	Been a patient in an Australian facility listed Organisms e.g. CPE) transmission risk area i			Producing	O Yes	O No		
initional Screer	Right click on this box and select "Reference							
sech and Sen:	Any symptoms requiring transmission based				O Yes	O No		
d of Life/Adva	e.g. fever & rash, influenza-like or diarrhoea							
ient Health Qu	Any symptoms requiring airborne precaution shingles or TB?	is? eg. measles, ch	icken pox,	/disseminated	O Yes	O No		
charge Plannir								
	Contact with someone who has Carbapenem Candida auris	ase-producing orga	anisims (e	.g. CPE) or	O Yes	O No		
	Contact with a person with suspected/confir a country with widespread Novel Coronaviru- fever (now or history of) and/or cough/ diffu	s or MERS in past 4			O Yes	C No]
		el Coronavirus high risk ance	countries: C	hina, Hong Kong				
	Additional Syndromic/MDRO Surveille History of CPO (includes CPE/CRE)		Countries: C	hina, Hong Kong	1			
	Additional Syndromic/MDRO Surveille History of CPO (includes CPE/CRE)		O Yes	C No]			1
	Additional Syndromic/MDRO Surveille]			•
	Additional Syndromic/MDRO Surveille History of CPO (includes CPE/CRE)		O Yes	C No]]]			
	Additional Syndromic/MDRO Surveill History of CPO (includes CPE/CRE) History of clostridium difficile		O Yes	O No O No]]]			
	Additional Syndromic/MDRO Surveill History of CPO (Includes CPE/CRE) History of clostridium difficile Recent exposure to communicable disease		O Yes O Yes O Yes	C No C No C No]]]]			•
	Additional Syndromic/MDRO Surveill History of CPO (Includes CPE/CRE) History of clostridium difficile Recent exposure to communicable disease History of Candida Auris		O Yes O Yes O Yes O Yes	 ○ No ○ No ○ No ○ No]]]]			•
	Additional Syndromic/MDRO Surveill History of CPO (Includes CPE/CRE) History of clostridium difficile Recent exposure to communicable disease History of Candida Auris History of abscess	ance	O Yes O Yes O Yes O Yes O Yes	No]]]]			
	Additional Syndromic/MDRO Surveill History of CPO (includes CPE/CRE) History of clastridium difficile Recent exposure to communicable disease History of Candida Auris History of abscess History of chronic skin condition	ance nase (ESBL)	Yes Yes Yes Yes Yes Yes Yes Yes	С No С No С No С No С No С No]]]]]]			
	Additional Syndromic/MDRO Surveill History of CPO (includes CPE/CRE) History of clostridium difficile Recent exposure to communicable disease History of Candida Auris History of abscess History of chronic skin condition History of Extended- Spectrum Beta- Lactor	ance nase (ESBL) us Aureus (MRSA)	Yes Yes Yes Yes Yes Yes Yes Yes Yes	 No 				
	Additional Syndromic/MDRO Surveill History of CPO (Includes CPE/CRE) History of clostridium difficile Recent exposure to communicable disease History of Candida Auris History of abscess History of chronic skin condition History of Extended- Spectrum Beta-Lactan History of Methicillin Resistant Staphylococc	ance nase (ESBL) us Aureus (MRSA) us (VRE)	C Yes C Yes C Yes C Yes C Yes C Yes C Yes C Yes C Yes C Yes	C No C No C No C No C No C No C No C No				•